These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 16937302)

  • 1. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
    Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
    Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
    Chowdhury FU; Bradley KM; Gleeson FV
    Clin Radiol; 2008 Dec; 63(12):1297-309. PubMed ID: 18996259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET and PET/CT for colorectal cancer.
    Delbeke D; Martin WH
    Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
    Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
    J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
    Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
    Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
    Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
    Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review.
    Chowdhury FU; Shah N; Scarsbrook AF; Bradley KM
    Postgrad Med J; 2010 Mar; 86(1013):174-82. PubMed ID: 20237012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
    Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
    Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
    Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
    Kaya AO; Coskun U; Unlu M; Akdemir UO; Ozdemir NY; Zengin N; Benekli M; Yildiz R; Yaman E; Ozturk B; Gumus M; Uner A; Yamac D; Ucgul E; Buyukberber S
    Asian Pac J Cancer Prev; 2008; 9(4):683-6. PubMed ID: 19256759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination.
    Czernin J; Benz MR; Allen-Auerbach MS
    Eur J Radiol; 2010 Mar; 73(3):470-80. PubMed ID: 20097498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.